via NetworkNewsAudio — Predictive Oncology (NASDAQ: POAI) today
announces that Company director and CEO Dr. Carl Schwartz, in an
interview with NetworkNewsWire (NNW), discussed the Predictive
Oncology’s distinctive business model and significant changes
management is making to position the Company for the future.
The broadcast of the exclusive audio interview produced by NNW,
a financial news and content distribution company and one of 40+
brands in the InvestorBrandNetwork (IBN), can be heard at
http://nnw.fm/o7Ysq.
The interview discusses the evolution of Predictive Oncology.
“As we moved forward, we changed our focus to artificial
intelligence through our wholly owned subsidiary Helomics,”
Schwartz said. Another key change came with the acquisition of a
second wholly owned subsidiary, TumorGenesis. Continuing this
growth strategy, the Company is now is in the process of acquiring
two biological firms: Soluble Therapeutics and BioDtech.
“Predictive’s major asset is its Helomics subsidiary and its
proprietary database of over 150,000 cancer tumors covering over
137 types of cancers, with over 30,000 tumors related to ovarian
cancer, which is sort of our specialty. In fact, this is the
largest inventory of its kind in the world,” stated Schwartz.
Schwartz further explained that this phenomenal collection was
amassed over the last two decades by physicians sending in
cancerous tumors to be tested with the known therapies of the time.
“The results of these tests were in turn sent back to the referring
physicians to be used as a guide or a reference as desired for
treatment of the evaluated tumor,” he said. “And the evaluated
tumor was placed back in the physician’s therapy inventory. That’s
how we amassed all these tumors.”
The Company’s ultimate goal for Helomics is to replicate the
path taken by Foundation Medicine and its relationship with Roche
Pharmaceutical in obtaining funds for research.
“We ultimately need to prove that we’re able to sequence, which
is genetically profile our tumors, and do what is called a ‘reach
back,’ or examination of what eventually happened to these patients
over an extended period of time,” Schwartz said. “I want to
strongly emphasize that Helomics is the only company with the
ability to do this ‘reach back’ at this time because only we have a
patient history. I want to make sure I emphasize that we’re the
only company that has this history.”
During the interview, Schwartz also pointed out other key
components of Predictive Oncology’s strategic plan moving forward,
including its CancerQuest 2020 project conducted in partnership
with UPMC Magee, an agreement with Interface Diagnostics to do a
thyroid study utilizing POAI’s AI model, and other projects
involved precision medicine trials and prostate cancer.
“This should be enough information to demonstrate our ability to
validate our process,” Schwartz said. “We will then go to pharma
industry for major funding. And we’re pretty excited about this. We
think we’re going to finally get to the top of the heap here very
shortly.”
Listen to the full interview with Predictive Oncology’s Carl
Schwartz at http://nnw.fm/o7Ysq
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three
segments (Domestic, International and other), which contain four
subsidiaries: Helomics, TumorGenesis, Skyline Medical and Skyline
Europe. Helomics applies artificial intelligence to its rich data
gathered from patient tumors to both personalize cancer therapies
for patients and drive the development of new targeted therapies in
collaborations with pharmaceutical companies. Helomics’
CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient treatment decisions, by
providing an evidence-based roadmap for therapy. In addition to its
proprietary precision oncology platform, Helomics offers boutique
CRO services that leverage its TruTumor(TM), patient-derived tumor
models coupled to a wide range of multi-omics assays (genomics,
proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform to provide a tailored solution to its
clients’ specific needs. Predictive Oncology’s TumorGenesis
subsidiary is developing a new rapid approach to growing tumors in
the laboratory, which essentially “fools” cancer cells into
thinking they are still growing inside a patient. Its proprietary
Oncology Discovery Technology Platform kits will assist researchers
and clinicians to identify which cancer cells bind to specific
biomarkers. Once the biomarkers are identified they can be used in
TumorGenesis’ Oncology Capture Technology Platforms which isolate
and help categorize an individual patient’s heterogeneous tumor
samples to enable the development of patient specific treatment
options. Helomics and TumorGenesis are focused on ovarian cancer.
Predictive Oncology’s Skyline Medical division markets its patented
and FDA-cleared STREAMWAY System, which automates the collection,
measurement and disposal of waste fluid, including blood,
irrigation fluid and others, within a medical facility, through
both domestic and international divisions. The company has achieved
sales in five of the seven continents through both direct sales and
distributor partners. For more information, please
visit www.Predictive-Oncology.com.
About NetworkNewsAudio (NNA)
NetworkNewsAudio (“NNA”) allows you to sit back and listen to
market updates, CEO interviews and a company AudioPressRelease
(“APR”). These audio clips provide snapshots of position,
opportunity and momentum. NNA can assist your company by
cutting through the overload of information in today's market. NNA
brings its Client Partners unparalleled visibility, recognition and
brand awareness. NNA is just one site within our sizable family of
40+ brands within the InvestorBrandNetwork (“IBN”). IBN is a
comprehensive provider of news and original articles; we aggregate
and syndicate this content for much bigger impact. IBN also adds
Press Release Enhancement and a full array of social media
communication solutions and has amassed a collective audience that
includes millions of social media followers. As a multifaceted
financial news and distribution company with an extensive team of
journalists and writers, IBN has the unparalleled ability to reach
a wide audience comprising investors, consumers, journalists and
the general public with an ever-growing distribution network of
5,000+ key syndication outlets across the nation.
IBN is where news, content and information
converge.
For more information, visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website applicable to all content provided by
IBN, wherever published or
re-published: http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
InvestorBrandNetwork (IBN) Los Angeles, California
www.InvestorBrandNetwork.com 310.299.1717 Office
Editor@InvestorBrandNetwork.com
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024